Selank shows up in research-peptide conversations mostly through two questions: what does it actually do, and how much of it do researchers use. The first question has a reasonably clear research trail. The second is messier — most of what circulates online as a “Selank dosage” is copied from other retailer blogs, not pulled from the underlying studies. This article works from the published research directly: the doses researchers have actually used, in which models, and what those studies found. If you're starting from the product itself, Selank nasal spray is the pre-formulated research format — intranasal administration is also the route used in the human trial covered below.
Selank is a synthetic heptapeptide analog of tuftsin, a naturally occurring immune-signaling fragment of immunoglobulin G. It was developed at Russia's Institute of Molecular Genetics and is registered there as a pharmaceutical for anxiety-related indications. Outside Russia, it's an unapproved research compound. For a fuller comparison against Semax, the structurally unrelated peptide it's most often confused with, see our Semax vs Selank comparison.
How Selank Is Proposed to Work
Selank's proposed anxiolytic mechanism runs through two overlapping pathways. It appears to modulate the brain's GABA system — the primary inhibitory neurotransmitter system, and the same broad target class as benzodiazepines — without producing the sedative profile associated with classical GABAergic drugs. It also appears to slow the breakdown of enkephalins, endogenous peptides involved in mood and stress regulation, which may be a second route to the same anxiolytic effect [1].
Separately, because Selank is derived from tuftsin, an immune-signaling peptide, it has been studied for immunomodulatory effects consistent with that origin. Animal research has examined its influence on cytokine production and immune-cell gene expression, a line of investigation less developed than the anxiolytic research but mechanistically distinct from it [2].
Selank and BDNF: A Less-Discussed Mechanism
Brain-derived neurotrophic factor (BDNF) modulation is usually discussed in connection with Semax, not Selank — our own Semax vs Selank comparison frames BDNF as Semax's territory. But it's a less commonly cited part of the literature that Selank has been studied for hippocampal BDNF expression as well. In a rat study, intranasal Selank was reported to increase BDNF mRNA levels in the hippocampus at 3 hours post-administration and BDNF protein levels at 24 hours, at doses of 250 and 500 μg/kg [3].
This doesn't mean Selank and Semax work the same way. The GABA/enkephalin pathway remains Selank's primary, better-characterized mechanism, and a single rodent study on a secondary pathway is not the same evidentiary weight as the anxiolytic literature. It's included here because dosage questions about Selank often assume the anxiolytic research is the whole picture, and it isn't.
What Dosage Has Been Used in Published Research
There is no established, consensus Selank dosage in the published literature the way there is for some better-studied research peptides. What exists is a small number of studies, in different species and different delivery routes, each using a dose chosen for that specific experiment — not a converging range that would support a single confident number.
Animal Studies
- Kasian et al. (2017): 300 μg/kg in rats, in an active-avoidance and unpredictable chronic mild stress model, examining Selank's effect alongside diazepam [1].
- Inozemtseva et al. (2008): 250 and 500 μg/kg intranasal in rats, measuring hippocampal BDNF mRNA and protein expression [3].
- Kolomin et al. (2014): 100 μg/kg intraperitoneal in mice, measuring inflammation-related gene expression in the spleen [2].
Taken together, the animal literature clusters in a roughly 100–500 μg/kg range, but across three different endpoints, two species, and two delivery routes. Per-kilogram animal doses don't translate directly to human dosing — this is a general limitation of preclinical pharmacology, not specific to Selank — so this range should be read as a description of what's been studied, not a protocol.
The Human Trial
The one published human study is a 2008 Russian comparative trial of 62 patients with generalized anxiety disorder and neurasthenia, 30 given Selank and 32 given medazepam (a benzodiazepine used clinically in Russia) [4]. Selank was administered intranasally under clinical supervision. The published abstract-level source does not report a specific microgram dose, which is itself a useful data point: even the primary human evidence doesn't establish a standard number, only that intranasal administration was used in a supervised clinical-trial context.
Why There's No Single Number
For researchers converting a stock concentration into a working spray volume, the reconstitution arithmetic is the same regardless of which compound is involved — our peptide calculator can handle that part. What it can't do, and what nothing currently in the published literature supports, is a Selank-specific recommended dose. The calculator's research-dose reference is built from studies with converging evidence; Selank's current literature doesn't yet meet that bar.
What the Research Has Studied Selank For
Anxiolytic Effects
In rodent models of unpredictable chronic mild stress, Selank has been studied both alone and alongside diazepam, with researchers reporting anxiolytic effects described as comparable to classical anxiolytics but without the same sedative signature [1]. In the human comparative trial, Selank's anxiolytic effect on Hamilton and Zung anxiety scales was reported as comparable to medazepam, with an additional antiasthenic and mildly psychostimulant effect that the comparator drug did not produce [4].
Immune-Linked Effects
Consistent with its tuftsin origin, Selank has been studied for effects on immune-cell gene expression. Research examining spleen tissue in mice found changes in the expression of inflammation-related genes following Selank administration, though this line of research is earlier-stage and less developed than the anxiolytic literature [2].
Hippocampal BDNF Expression
As covered above, a rat study found that intranasal Selank increased hippocampal BDNF mRNA and protein expression [3]. BDNF supports neuronal survival and is involved in learning and memory consolidation, which is why this finding is sometimes cited in discussions of Selank's cognitive-adjacent research profile — though it remains a single preclinical study, not a replicated finding.
The Human Evidence Gap and Safety Considerations
Selank's human evidence consists of one comparative clinical trial, conducted and published in Russia, measured against an active comparator drug rather than a placebo, and not independently replicated outside that jurisdiction [4]. That's a meaningfully thinner evidence base than a placebo-controlled, internationally replicated trial would provide, even though the reported results were positive.
Selank is not approved by the FDA or the European Medicines Agency. It's classified as an unapproved research compound outside Russia. As with any research peptide, product quality varies significantly by supplier — batch-specific certificates of analysis with HPLC purity and mass spectrometry identity confirmation are the baseline standard for sourcing, regardless of which compound is involved.
The Takeaway
Selank has a real, if narrow, research base: a Russian human trial comparing it to a benzodiazepine, and a handful of rodent studies on GABAergic, immune, and BDNF-linked pathways using doses that cluster loosely around 100–500 μg/kg. What the literature does not currently support is a single, confident “standard dosage” — the studies use different species, routes, and endpoints, and the one human trial doesn't publish a specific dose at all. Anyone researching Selank should treat published animal doses as a description of what's been studied, not a protocol, and should treat the human trial as an encouraging but singular data point rather than an established clinical standard.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
- Kasian, A., Kolomin, T., Andreeva, L., et al. (2017). Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behavioural Neurology, 2017, 5091027.
- Kolomin, T., Morozova, M., Volkova, A., et al. (2014). The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Molecular Immunology, 58(1), 50-55.
- Inozemtseva, L. S., Karpenko, E. A., Dolotov, O. V., Levitskaya, N. G., Kamensky, A. A., Andreeva, L. A., & Grivennikov, I. A. (2008). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences, 421(1), 241-243.
- Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(4), 38-48.
Labs sourcing material for the protocols discussed above can find selank nasal spray in stock — US-shipped and US-tested, with a third-party COA for every batch.
